The significance of our study is that AAV1.NT-3 gene therapy, administered after the onset of neuropathy leads to meaningful improvements in functional, electrophysiological and histopathological phenotype of Cx32 KO model for CMTX1, another CMT subtype with primary SC genetic defect, similar to CMT1A. This evidence concerns the gene NTF3 and Charcot-Marie-Tooth disease.